Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Brigitta G. Baumert, Roger Stupp, Martin J. van den Bent et al.|The Lancet Oncology|2016

Cited by 504